Mortality After Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer

• Published in: JNCI : Journal of the National Cancer Institute Vol. 105; no. 10; pp. 711 - 718
• Main Authors: Hoffman, R. M., Koyama, T., Fan, K.-H., Albertsen, P. C., Barry, M. J., Goodman, M., Hamilton, A. S., Potosky, A. L., Stanford, J. L., Stroup, A. M., Penson, D. F.
• Format: Journal Article
• Language: English
• Published: Cary, NC Oxford University Press 15.05.2013; Oxford Publishing Limited (England)
• Subjects: Aged; Biological and medical sciences; Humans; Male; Medical sciences; Mens health; Middle Aged; Mortality; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Nephrology. Urinary tract diseases; Prostate cancer; Prostatectomy - methods; Prostatic Neoplasms - mortality; Prostatic Neoplasms - radiotherapy; Prostatic Neoplasms - surgery; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Human; Nephrology; Urinary system disease; Prostate disease; Mortality; Early stage; Malignant tumor; Radiotherapy; Electrontherapy; Urology; Extracorporeal irradiation; Cancerology; Treatment; Surgery; Prostatectomy; Male genital diseases; Prostate cancer; Comparative study; Cancer
• ISSN: 0027-8874; 1460-2105; 1460-2105
• DOI: 10.1093/jnci/djt059

No randomized trials have compared survival outcomes for men with localized prostate cancer (PC) being treated with radical prostatectomy (RP) or external beam radiotherapy (EBRT). The goal of the study, therefore, was to estimate the association of RP (compared with EBRT) with overall and PC mortality. We analyzed an observational cohort from the population-based Prostate Cancer Outcomes Study, which included men aged 55 to 74 years diagnosed with localized PC between October 1994 and October 1995 who underwent either RP (n = 1164) or EBRT (n = 491) within 1 year of diagnosis. Patients were followed until death or study end (December 31, 2010). Overall and disease-specific mortality were assessed with multivariable survival analysis, with propensity scores to adjust for potential treatment selection confounders (demographics, comorbidities, and tumor characteristics). All statistical tests were two-sided. After 15 years of follow-up, there were 568 deaths, including 104 from PC. RP was associated with statistically significant advantages for overall (hazard ratio [HR] = 0.60, 95% confidence interval [CI] = 0.53 to 0.70, P <.0001.) and disease-specific mortality (HR = 0.35, 95% CI = 0.26 to 0.49, P <.0001.). Mortality benefits for RP were also observed within treatment propensity quintiles, when subjects were pair-matched on propensity scores, and in subgroup analyses based on age, tumor characteristics, and comorbidity. Population-based observational data on men diagnosed with localized PC in the mid-1990s suggest a mortality benefit associated with RP vs EBRT. Possible explanations include residual selection bias or a true survival advantage. Results might be less applicable for men facing treatment decisions today.